Mesenchymal stem cells: mechanisms and role in bone regeneration

Yunhao Qin, Junjie Guan, Changqing Zhang

ABSTRACT
Stimulating bone growth and regeneration, especially in patients with delayed union or non-union of bone, is a challenge for orthopaedic surgeons. Treatments employed for bone regeneration are based on the use of cells, biomaterials and factors. Among these therapies, cell treatment with mesenchymal stem cells (MSCs) has a number of advantages as MSCs: (1) are multipotent cells that can migrate to sites of injury; (2) are capable of suppressing the local immune response; and (3) are available in large quantities from the patients themselves. MSC therapies have been used for stimulating bone regeneration in animal models and in patients. Methods of application range from direct MSC injection, seeding MSCs on synthetic scaffolds, the use of gene-modified MSCs, and hetero-MSCs application. However, only a small number of these cell-based strategies are in clinical use, and none of these treatments has become the gold standard treatment for delayed or non-union of bone.

INTRODUCTION
Our understanding of mesenchymal stem cells (MSCs) is based on work carried out in the 1960s by Friedenstein and coworkers who observed that the bone marrow is a source of stem cells for mesenchymal tissue. They observed that these cells are plastic-adherent, fibroblast-like cells that can differentiate into chondrocytes, adipocytes and osteoblasts. Much research has shown that MSC treatment may be very useful for bone repair. The treatment offers the advantages but not the disadvantages of embryonic stem cells (ESCs): MSC use presents less risk of malignant disease development and avoids the ethical problems associated with ESCs. Although great success has been achieved with MSCs in promoting bone regeneration in animal models, there are a number of gaps in our knowledge which need to be addressed before this treatment can be widely applied in clinical practice. For example, the mechanism by which MSCs stimulate and mediate bone regeneration in vivo is unknown. Also, the relatively few in vivo experiments require in vitro expansion; however, it is difficult to maintain a stable phenotype in vitro.

FEATURES OF MSCS
MSCs are derived from a number of sources and act as immune suppressors and endocrine secretors, thereby exerting their regenerative effect. Most parts of the human body including the bone marrow, adipose tissue, skin, liver and placenta produce MSCs. However, it is important to identify their source as MSCs from different origins have different potential to differentiate into various cell lineages. This can be done by identifying cluster of differentiation (CD) markers, since MSCs from different sources have distinct CD markers; for example, the typical CD markers of MSCs from non-haematopoietic tissue are CD34<−, CD11a<−, CD45<− and CD19<−, while the typical CD markers of bone-derived MSCs are CD105, CD73, CD90, CD45<−, CD34<− and HLA-DR<−. In addition to identifying their origin, the CD markers also indicate MSC function and features. According to research by Yannarelli et al., CD146 MSCs are vigorous and can self-renew: after gene expression of CD146 is downregulated or silenced, this self-renewal ability is weakened or disappears.

The most important feature of MSCs is that, under certain in vitro conditions, the cells are capable of differentiating into mesodermal cells such as osteoblasts, adipose cells, cartilage cells or skeletal muscle cells. This process of differentiation is a basic step in promoting regeneration. In addition, research has shown that bone regeneration can be promoted by adding dexamethasone, ascorbic acid and β-glycerophosphate to the culture medium, while the addition of dexamethasone, insulin and rosiglitazone in the medium induces MSCs to differentiate into adipose cells.

MSCs inhibit the immune response in two ways: by the contact immune response and by the non-contact immune response. Bartholomew et al. found that, through the contact immune response, MSCs could inhibit the immune response of lymphocytes, prevent the maturation of antigen-presenting cells and weaken the immune function of natural killer cells. Since MSCs can act as immune suppressors, they have been used to treat several immune diseases. Le Blanc et al. successfully used in vitro expanded MSCs to ameliorate severe graft versus host disease (GVHD). The median dose of MSCs used in their study was 1.4×10⁶/kg. Of the 55 patients treated, 27 received one dose, 22 received two doses, four received three doses, one received four doses and one received five doses. Thirty patients achieved a complete response and nine patients showed improvement. However, three patients developed recurrent malignant disease and one patient developed acute myeloid leukaemia. The study results showed that the 1-year mortality of patients treated with MSCs was lower than for patients not treated with MSCs (11 of 30 patients (37%) died in the MSC treatment group compared with 18 of 25 patients (72%) in the non-MSC treatment group). Furthermore, the 2-year survival rate of patients in the MSC treatment group was higher than in the non-MSC treatment group (16 of 30 patients (53%) in the MSC treatment group survived...
INFLUENCES ON THE DIFFERENTIATION OF MSCS

Target cell lineage differentiation is critical for the regenerative effect of MSCs, and part of the mechanism of this process has now been elucidated. The microenvironment has the strongest influence on the maturation and differentiation of MSCs, but cell-to-cell communication, physical factors and cell structure have also been found to have an effect. However, the mechanisms by which these factors affect MSCs are still not fully understood.

The microenvironment plays a key role in controlling MSC differentiation. The process is influenced by the presence of different proteins, hormones and growth factors. Bone morphogenetic protein (BMP) is the classic osteogenic protein, and Liu et al have elucidated the exact mechanism by which BMP affects MSCs. This protein generates the transcription factor Smads by combining with type I or II serine/threonine receptor and the Ca2+ pathway to promote the osteogenic differentiation of MSCs.

APPLICATION OF MSCS

Several approaches to MSC treatment have been used to promote bone regeneration in both animal models and clinical practice. The most common MSC treatment is direct injection. Some studies have also shown that attaching MSCs on a bioscaffold is an effective way to treat non-union of bone. The effectiveness and safety of gene-modified and hetero-MSCs have also been explored in animal models.

Direct injection of MSCs

For direct injection of MSCs, bone marrow is usually aspirated from the iliac crest and injected at the site of bone non-union. The aspirated mixture contains many MSCs and is called bone marrow aspirate concentrate (BMAC). The effectiveness of direct injection of MSCs has been shown in both animal experiments and clinical studies. A report by Lee et al described direct injection of MSCs with hyaluronic acid at defects on the medial femoral condyle in 27 pigs. The animals were killed 6 and 12 weeks later and results showed that the experimental group had cartilage regeneration while the control group demonstrated fibrous regeneration.

Results in animal models led to the use of MSCs to repair large bone defects in the clinical setting. In 1998, Connolly et al used direct injection of BMAC to heal non-union of the tibia in 20 patients, 18 of whom showed full recovery after 6–8 months. Other clinical studies also support the effectiveness of the direct injection of MSCs. Hermigou and Beaufort found a positive correlation between the quantity of BMAC administered by percutaneous injection and mineralised bone.
formation to treat non-union of the tibia, and reported good results in 60 patients.

Although direct injection is clearly effective in promoting bone regeneration, some drawbacks of this technique have been reported in animal studies. These include the development of local ischaemia following direct injection into an artery and micro embolisation in the lungs following intravenous injection. In a related experimental study, Janowski et al. directly injected MSCs into the carotid artery of rats and found that an injection velocity higher than 0.2 mL/min could cause local ischaemia; however, if fewer than 1×10^6 MSCs were used, the injection did not cause local ischaemia.

The effectiveness and safety of direct injection of MSCs in humans still needs further investigation and assessment.

MSCs and biomaterial scaffolds

Direct injection of MSCs has been found to be ineffective for very large bone defects or non-union of bone. However, such cases can be effectively treated by attaching MSCs to a biomaterial scaffold. The ideal biomaterial scaffold must be biodegradable, biocompatible, support colony formation and be a good bone inducer. Hydroxyapatite (HA) and tricalcium phosphate (TCP) are commonly used in clinical practice to promote bone regeneration because of their good bone induction properties.

The effectiveness of bioscaffolds has been confirmed by many researchers. Morishita et al. treated defects after tumour resection at the distal tibia by attaching autologous MSCs to HA to induce bone regeneration. The results showed that two patients were able to weight bear on the affected extremities 2 weeks after transplantation and one patient was able to weight bear 3 weeks after transplantation. A CT scan at 3 weeks showed a gradual increase in the density of the transplantation area. Furthermore, several studies have also investigated the use of in vitro expanded MSCs for the regeneration of bone. In a phase I clinical trial, Quarto et al. attached ex vivo expanded MSCs on HA to treat bone defects in three patients with successful results.

Materials are also being actively investigated for use as scaffolds for optimal outcomes in animal models. Fricain et al. successfully used a hydrophilic polysaccharide scaffold with nano-HA to induce bone regeneration. In vitro experiments showed that MSCs in a culture environment with low bone induction factors and attached to this type of scaffold were still able to congregate and express bone-specific markers. Additionally, animal models showed that this scaffold successfully and independently induced calcification of the surrounding tissue and bone formation. Biomaterial scaffolds with MSCs have been fully developed and numerous successful treatments have been conducted by researchers and doctors in both animals and humans. Three-dimensional (3D) prints of scaffolds using technologies such as rapid prototyping have also been used for developing scaffolds to promote bone regeneration. Duarte Campos et al. encapsulated MSCs into agarose hydrogels and made a 3D print, supported by fluorocarbon, and achieved good cell culture results.

However, more clinical trials are required to investigate the effectiveness, safety and side effects of the traditional method of attaching MSCs on biomaterials before it can be widely applied in clinical practice. Furthermore, it needs to be demonstrated that the new materials are superior to the more traditional ones.

Gene-modified MSCs

Delivering genes to enhance MSC function has been explored by many researchers, with BMP genes most commonly used to promote the bone formation activity of MSCs. Most gene-modified MSCs have been used in animal models.

The genetic technique can be utilised when MSCs are transplanted back into animals or patients after in vivo modification. Gamradt et al. investigated 24 mice with severe combined immunodeficiency. The mice were divided into two groups (12 mice in each group) and one group was treated with adenovirus and BMP-2 gene-transfected MSCs while the other group was treated with normal MSCs. The MSCs were transplanted into 3 mm defects in the left forelimb of the mice. Three mice from each group were killed at 3, 7, 14 and 21 days. X-rays at 7 days showed that the experimental group achieved bone formation before the control group. In addition, bone formation was much more stable in the experimental group than in the control group at 21 days.

Another way to obtain gene-modified MSCs is to directly inject a viral vector to transfect the gene at sites of non-union of bone. Ishihara et al. directly injected BMP-2 and BMP-6 transfected adenovirus at bone defects in horses to explore the regenerative effect. Radiographic assessment showed greater and earlier bone formation in the experimental group, while CT and biomechanical testing showed more mineralised callus and torsional strength. Histological evaluation showed that the bone defects in the experimental group had greater formation of mature cartilage and bone nodules.

The target gene can also be developed by using gene-activated matrix (GAM), which consists of collagenous scaffold with plasmid DNA encoding osteogenic products. When GAM is inserted into a bone lesion, host cells enter it, are transfected by the DNA and secrete the osteogenic gene product. The effectiveness of GAM in promoting bone regeneration has been investigated by Bonadio et al. GAM was implanted at sites of bone injury in dogs and the retention and expression of plasmid DNA were evaluated for at least 6 weeks. The results showed that the bone induction effect of GAM is stable, reproducible, dose-dependent and time-dependent.

Epigenetic modification and interference of RNA are major techniques commonly used to modify genes. Du et al. showed in vivo that a widely present histone demethylase FBXL11 could demethylate the epiregulin gene to inhibit osteogenic differentiation of MSCs. Furthermore, Zeng et al. found that miRNA-100 could bind to BMP-2 receptor and successfully inhibit osteogenic differentiation of adipose-derived MSCs.

Although promising results have been achieved in animal models, getting gene-modified MSCs into human clinical trials is a lengthy, expensive and frustrating process. Furthermore, safety is the top priority for any gene therapy, but safety testing requires pharmacology and toxicology studies and distribution analysis of the transferred genomes. In addition, it is complicated and expensive to develop clinical grade vectors. A further problem is how to develop non-invasive techniques to evaluate bone quality and mechanical strength.

Future prospects

Many researchers have studied the effects of MSCs in stimulating bone regeneration. Although results are very encouraging,
many problems remain. First, most experiments have explored in vitro or animal mechanisms and there is little information about the in vivo mechanisms of MSCs. Second, although MSCs have been applied in clinical practice and have been used to treat hundreds of patients, their efficacy is still inferior to that of bone autografts. Third, further studies are required to obtain the most viable MSCs through cell culture and expansion. Fourth, the efficacy of MSCs of various origins also needs further research and assessment. With the development of biomaterials and molecular techniques, MSCs will become more important in the current search for bone regeneration therapies.

Main messages

- Mesenchymal stem cells (MSCs) are multi-potent cells that derive from the bone marrow, migrate to sites of injury, promote bone regeneration and can inhibit immune responses.
- In vitro, MSCs can differentiate into mesodermal cells—osteoblasts, adipose cells and cartilage cells.
- MSCs have therapeutic potential and offer an approach for promoting bone regeneration and the efficacy of the treatment of transplantation.

Current research questions

- A better understanding of the in vivo mechanisms of action of mesenchymal stem cells (MSCs) is required.
- Methods to achieve viable quantities of MSCs through cell culture and expansion need to be developed.
- The efficacy of MSCs from different sources needs to be ascertained.

Key references


Self assessment questions

1. Which markers are typical of bone derived mesenchymal stem cells?
   A. CD105, CD73, CD90
   B. CD45, CD34, HLA-DR
   C. CD45, CD34, CD11

2. Which factors induce osteogenic differentiation by mesenchymal stem cells?
   A. Bone morphogenetic protein (BMP)
   B. Estrogen
   C. Vascular endothelial growth factor (VEGF)

3. Which biomaterials are commonly used in clinic practice?
   A. Hydroxapatite (HA)
   B. Tricalcium phosphate (TCP)
   C. LLPA

4. Which obstacles prevent the wide application of MSCs in clinic practice?
   A. Treatment efficacy has not been proven.
   B. There are ethical problems with using MSCs.
   C. The safety of MSCs needs further investigation.

5. Which are special features of MSCs?
   A. MSCs can suppress the immune response.
   B. MSCs can promote trauma regeneration.
   C. MSCs can differentiate into adipose tissue.

Contributors

YQ designed and wrote the manuscript. JG and CZ provided essential advice and revised the manuscript.

Competing interests

None.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


21 Lee KB, Hui JH, Song IC. Injectable mesenchymal stem cell therapy for large bone defects: three cases of cultured bone grafts derived from patients' mesenchymal stem cells. Artif Organs 2006;30:115–18.


Answers

1. (A) and (B).
2. (A) and (B).
3. (A) and (B).
4. (A), (B) and (C).
5. (A), (B) and (C).
Mesenchymal stem cells: mechanisms and role in bone regeneration

Yunhao Qin, Junjie Guan and Changqing Zhang

Postgrad Med J 2014 90: 643-647
doi: 10.1136/postgradmedj-2013-132387

Updated information and services can be found at:
http://pmj.bmj.com/content/90/1069/643

These include:

References
This article cites 38 articles, 1 of which you can access for free at:
http://pmj.bmj.com/content/90/1069/643#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/